Document:

exv10w20

Exhibit 10.20

2009 Corporate Bonus Plan Summary

     The following is a summary of key terms of SuccessFactors’ 2009 Corporate Bonus Plan. This
plan does not cover personnel under sales commission or other commission-based plans.

     The total bonus pool under the plan for 2009 would be based on achievement of various
performance targets. 50% of the total bonus pool would be funded based on achievement of
performance targets based on bookings, operating cash flow and renewals. These performance targets
would vary on a sliding scale basis, corresponding to payout multipliers ranging from 75% to 130%
of the target payout.

     The remaining 50% of the total bonus pool would be funded based on achievement of quarterly
performance targets based on bookings and cash flow, with 12.5% of the total bonus pool being the
target payout for each quarter. These quarterly performance targets would vary on a sliding scale
basis, corresponding to payout multipliers ranging from 80% to 130% of the target payout.

     Any bonus would be paid after the completion of the year. Employees must be employed at the
time of payment to be entitled to receive a bonus payment. Notwithstanding the plan, the total
bonus pool amount may be adjusted by the Compensation Committee or the Board of Directors in their
sole discretion. Any determination of performance, payment or other matter under this plan by the
Compensation Committee or the Board of Directors is binding. Individual bonus amounts are the
responsibility of Company management. With respect to executive officers of the Company, the CEO
shall recommend individual bonus amounts for approval by the Compensation Committee.

     Except as otherwise provided in an individual employment agreement or by applicable law in the
relevant jurisdiction: (i) participation in this plan is not an agreement (express or implied)
between the plan participant and SuccessFactors that the participant will be employed for any
specific period of time, nor is there any agreement for continuing or long-term employment; (ii)
the plan participant and SuccessFactors each have the right to terminate the employment
relationship at any time for any reason; and (iii) this at-will employment relationship can only be
modified by an agreement signed by the participant and SuccessFactors.

     This summary highlights the principal features of the SuccessFactors 2009 Corporate Bonus Plan
but does not describe every situation that can occur. The Compensation Committee and Board of
Directors retain the right to interpret, revise, modify or delete the plan at their sole discretion
at any time.

     This plan is intended to be effective for at least fiscal year 2009 and shall remain in effect
until amended or terminated by the Compensation Committee or Board of Directors.exv10w4

Exhibit 10.4

Amendment No. 1 to Loan Agreement

          This Amendment No. 1 to Loan Agreement, dated as of May 6, 2009 (this “Amendment”), is made
between Citigroup Global Markets Inc. (“Smith Barney” or “SB”) and the undersigned, Move, Inc.
(“Client”).

          Whereas, SB and Client have entered into that certain Loan Agreement dated as of May 8, 2008
(the “Loan Agreement”); capitalized terms used herein but not defined herein have the meaning given
to them in the Loan Agreement;

          Whereas, SB and Client desire to amend the Loan Agreement to extend the Maturity Date to
May 21, 2009;

          Now, therefore, SB and Client, for good and valuable consideration, the receipt of which is
hereby acknowledged, hereby agree as follows:

	 	1.	 	Amendment to Loan Agreement. The Loan Agreement is hereby amended as
follows:

	 	a.	 	Section 3 of the Loan Agreement is hereby amended and restated in its
entirety as follows:

“3.) Repayment. The Client agrees to pay on May 21, 2009 (“Maturity Date”)
any balance outstanding with respect to all Advances, including any accrued
interest and fees, as well as any costs of collection and reasonable attorneys’
fees and costs. The total amount owed by the Client described in the preceding
sentence is hereafter referred to in this Agreement as the “Loan Obligation”. The
Client may prepay the Loan Obligation in whole or in part without penalty at any
time prior to the Maturity Date.

	 	2.	 	No Other Amendment. Except as amended by Section 1 above, the Loan Agreement
remains in full force and effect.
	 
	 	3.	 	Governing Law. This Amendment will be governed by, and construed in
accordance with, the laws of the State of New York, without regard to the conflict of laws
rules of such State.
	 
	 	4.	 	Counterparts. This Amendment may be executed in any number of counterparts
and by different parties hereto on separate counterparts, each of which, when so executed
and delivered, shall be an original, but all such counterparts shall constitute one and
the same instrument.

     In witness whereof, the undersigned have executed this Amendment as of the date first
above-written.

	 	 	 	 	 	 	 	 	 
	MOVE, INC.	 	 	 	CITIGROUP GLOBAL MARKETS INC.
	 
	 	 	 	 	 	 	 	 
	By:

	 	/s/ Lewis R. Belote, III
	 	 	 	By:
	 	/s/ Richard A. Gemberling
	Name:

	 	 

Lewis R. Belote, III
	 	 	 	Name:
	 	 
 Richard
A. Gemberling
	Title:

	 	Chief Financial Officer
	 	 	 	Title:
	 	Managing Directorexv10w1

Exhibit 10.1

[LETTERHEAD OF HENRY SCHEIN, INC.]

February 27, 2009

Mr. David M. Mulder

Chief Financial Officer

Biolase Technology, Inc.

4 Cromwell

Irvine, California 92618

Dear Mr. Mulder:

This letter agreement shall serve to amend that certain License and Distribution Agreement, by and
between Henry Schein, Inc. (“HSI”) and Biolase Technology, Inc, (“Biolase”), dated as of August 8,
2006, as amended (the “Agreement”).

As of the date set forth above, the parties hereby agree as follows:

	 	1.	 	As a fundamental condition precedent to HSI entering into this letter agreement,
Biolase has informed HSI that it is taking actions to reduce its operating expenses to such
a level as to reach profitability, based on **** Biolase sales revenue of $**** on an
on-going basis, to be adjusted as minimums increase.
	 
	 	2.	 	Subject to Section 1 above, HSI agrees to make a firm minimum purchase commitment of
Waterlase Turbo MD (a Waterlase MD with an associated turbo handpiece kit) and Ezlase base
units and any other laser units (including the **** and ****) offered during the Term and
their related future iterations and their auxiliary components and accessories (the
“Lasers”) during the period commencing on the date hereof to March 31, 2010 (the “New
Initial Term”) and Non-Laser Products (as defined below) in the aggregate amount of $42.7
million (“**** Level”), to be purchased as follows: (i) $**** comprised of Waterlase Turbo
MD lasers and Turbo upgrade kits, which such purchase shall occur no later than March 2,
2009, (ii) commencing on March 15, 2009, (26) semi-monthly purchases of any Biolase
products during the New Initial Term for purchases of not less than $**** per semi-monthly
period (of which $**** will be Lasers and $**** will be non-Laser products, including
disposable products, warranty sales, training and replacement parts, etc. collectively
“Non-laser Products”), each such purchase to occur on the 15th and the last day of each
consecutive month (e.g, March 15, 2009, March 31, 2009, April 15, 2009, April 30, 2009,
etc.); and (iii) HSI agrees to make purchases of any Biolase products in the aggregate
amount of $**** (the “Initial International Purchase”) with regard to distribution of
products in the United Kingdom, Belgium, Luxembourg, Netherlands, Australia, New Zealand,
Austria, Spain, and Germany or elsewhere in the world. The Initial International Purchase
shall occur no later than March 2, 2009. With respect to all purchases in this Section 2
made in February of 2009, HSI shall pay Biolase all of the purchase price on March 2, 2009
in respect of

 

			
	****	 	Certain confidential information contained in this document, marked with four asterisks, has
been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule
24b-2 of the Securities Exchange Act of 1934, as amended.

 

 

	 		 	(i) and (iii) above ($**** in the aggregate). Other payments in respect of purchases
hereunder shall be due upon receipt, of the applicable products. These purchases may be
purchased by HSI through HSI’s divisions or subsidiaries in the United States or Canada or
elsewhere in the world. Biolase will make the products available to HSI and, in accordance
with the parties’ standard business practice, promptly supply HSI with any products so
ordered. HSI and its affiliates, under the Agreement or any related agreements for the sale
of Biolase products anywhere in the world, shall have no product purchase obligations other
than as set forth herein. Notwithstanding anything contained herein to the contrary,
purchases by HSI of **** shall not be part of the purchases set forth in (i) through (iii)
above.
	 
	 	3.	 	With respect to **** Waterlase C-100 ****, Biolase and HSI agree to work together in
good faith to reach agreement upon a strategy for **** Waterlase C-100 **** no later than
April 15, 2009, with an agreed upon **** no later than ****.
	 
	 	4.	 	If sales exceed HSI targeted levels of $**** in Lasers of such year, ****% of such
excess sales of Lasers will be **** and ****% will be **** Lasers ****; provided, however,
that the parties will negotiate in good faith such percentages if ****.
	 
	 	5.	 	During the New Initial Term, Biolase shall exclusively sell its products through HSI in
the Territory, and shall not sell such products directly or through other distributors, and
HSI shall have the right to distribute the products through third-party distributors if it
so elects, provided that such third-party distributors sell to end-users permitted under
the Agreement “Territory” shall be defined as the United States, United Kingdom, Belgium,
Luxembourg, Netherlands, Canada, Spain, Germany, Austria, Australia, and New Zealand,
Subject to Biolase’s contractual obligations in respect of sales in markets governed by
existing distribution agreements in effect as of the date hereof, HSI shall have the right
to exclusively sell in other countries throughout the world. Biolase will consider in good
faith extending exclusivity in certain specific markets **** based upon HSI’s performance
in such markets.
	 
	 	6.	 	HSI may, at its option, extend this letter agreement for two additional one-year terms,
upon written notice given on or before February 1, 2010 or February 1, 2011 (for second
renewal) given by Schein to Biolase prior to the expiration of the New Initial Term (or the
then expiring additional one-year term, as the case may be); provided that HSI may only be
permitted to exercise an option to extend the then current term if it shall agree in
writing to purchase from Biolase a minimum aggregate amount of products purchased during
such additional term equal to (i) (for the first renewal term) the **** (a) $**** and (b)
**** of the amount of products actually sold by Biolase to HSI during the New Initial Term

 

			
	****	 	Certain confidential information contained in this document, marked with four asterisks, has
been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule
24b-2 of the Securities Exchange Act of 1934, as amended.

2

 

	 	 	 	(adjusted pro rata for 12 months); provided, however, that if HSI shall not have **** of
Lasers by $**** from the **** as of ****, measured ****, then HSI shall only be required to
purchase the **** (A) $**** or (B) **** of the amount of products actually sold by Biolase to
HSI during the New Initial Term (adjusted pro rata for 12 months), and (ii) (for the second
renewal term) the greater of (x) **** of the commitment for the prior renewal term and (y)
**** of the amount of products actually sold by Biolase to HSI during the first renewal term;
provided, however, that if HSI shall not have **** of Lasers by $**** from the **** as ****,
measured at ****, then HSI shall only be required to purchase the greater of (X) **** of the
commitment for the prior renewal term and (Y) **** of the amount of products actually sold by
Biolase to HSI during the first renewal term. The New Initial Term, together renewal terms,
if any, with shall be the “Term” of the Agreement and all covenants and provisions
restricting HSI or its affiliates, anywhere in the world under this Agreement or any related
agreement, including in respect of selling competing products, shall have no force or effect
upon the termination of this Agreement or expiry of Term. The parties will cooperate to
maximize sales of Biolase products after the expiry or termination of the Agreement.
	 
	 	7.	 	With respect to existing Waterlase MD and Ezlase inventory, subject to applicable law
(e.g. export laws), HSI agrees to use commercially reasonable efforts and to work in good
faith to **** through new international markets, among other places, with a **** Lasers by
a ****, through sales of Lasers in international markets.
	 
	 	8.	 	The cost of the Waterlase Turbo MD systems to HSI will be $**** in the United States
and Canada, and Biolase will **** on the warranty applicable to the Laser products from
**** to HSI. The cost of the current Ezlase system to HSI will **** be $**** for the United
States and Canada. For the avoidance of doubt, HSI shall determine the end-user customer
pricing.
	 
	 	9.	 	Upon the launch of the new turbo handpiece (expected to be the date hereof), Biolase
will upgrade HSI’s existing inventory with new turbo handpieces and related hardware and
software and HSI will purchase turbo handpieces as follows: solely with respect to HSI’s
existing on-hand inventory, for the payment of $****, Biolase will provide Schein with one
turbo handpiece kit and the related turbo handpiece software (turbo handpiece software to
be installed by HSI technicians during end-user installation) for each unit of existing
inventory. The stand-alone turbo handpiece upgrade kit for sale to the existing installed
base upgrade shall be priced to HSI at $**** per upgrade kit. The upgrade kits will be
completed in approximately **** days of such launch.

 

			
	****	 	Certain confidential information contained in this document, marked with four asterisks, has
been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule
24b-2 of the Securities Exchange Act of 1934, as amended.

3

 

	 	10.	 	HSI will assume the following functions that Biolase had previously performed
under the Agreement:

	 	a.	 	Support at certain trade shows, as determined by the parties
	 
	 	b.	 	Notwithstanding the foregoing, Biolase agrees to provide “over the shoulder”
demonstrations during the New Initial Term (and during each additional renewal term).
	 
	 	c.	 	HSI will use all reasonable efforts to secure the services of ****  to serve as a “luminary/trainer” in respect of the products.
	 
	 	d.	 	HSI will provide facilities appropriate for the purpose of providing WCLI seminar
programs, and will provide full related support expenses, including but limited to
honorariums for luminaries, accommodations for luminaries, travel for luminaries, and food
for participants (total estimated costs to be ($****-$****), with an estimated cost of
$**** per seminar program)
	 
	 	e.	 	Both parties shall endeavor to improve sales and to agree upon further
marketing efforts to accelerate sales and increase productivity.

	 	11.	 	In countries in which HSI distributes the Biolase products but does not have
exclusivity, Biolase will not offer the products to other distributors, wholesalers or
other similar entities on terms and conditions more favorable than those provided to HSI,
without also making any such more favorable terms or conditions available to HSI.
	 
	 	12.	 	HSI will continue to provide Level 1 service and Biolase will continue to provide all
the services it currently performs, including Level 2 service.
	 
	 	13.	 	To secure the $**** payment, Biolase will agree to enter into a security agreement to
be provided by HSI following the execution of this letter agreement containing those terms
and conditions customary and ordinary for such purpose, and will consent to the filing of
the related UCC or UCCs to effect a security interest for the benefit of HSI in Biolase’s
inventory, equipment and other tangible assets; provided that HSI shall agree to release
such security upon receipt of the products deliverable in respect of such $**** payment.
	 
	 	14.	 	In any country in which Biolase does not currently sell its products (a “New
Territory”), if Biolase determines to sell its products in such New Territory through the
distribution channel, HSI shall have the first right to sell such products on terms and
conditions to be agreed upon by the parties; provided that if the parties do not so agree
in good faith within fifteen (15) days upon notice to HSI, Biolase may utilize another
distributor in such New Territory provided that such distributor is not offered terms and
conditions more favorable to those offered to HSI.
	 
	 	15.	 	All amounts herein reference U.S. dollars. This letter agreement amends certain terms
and conditions of the Agreement. All other terms and conditions of the Agreement that are
not modified by this letter agreement are hereby ratified and

 

			
	****	 	Certain confidential information contained in this document, marked with four asterisks, has
been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule
24b-2 of the Securities Exchange Act of 1934, as amended.

4

 

	 	 	 	confirmed in all respects, and shall remain in full force and effect. Should there be any
conflict between the teens and conditions contained in this letter agreement and the
Agreement, the terms and conditions of this letter agreement shall govern and control.

Please acknowledge your agreement to the foregoing terms and conditions by executing this letter
agreement.

Regards,

	 	 	 	 	 
	 	 	 
	 	/s/ Brian S. Watson
 	 
	 	Vice President, Strategic and Business Planning 

Henry Schein, Inc. 	 
	 	 	 
	 
	 	 	 
	 	/s/ David M. Mulder
 	 
	 	Chief Financial Officer 	 
	 	Biolase Technology, Inc. 	 
	 

 

			
	****	 	Certain confidential information contained in this document, marked with four asterisks, has
been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule
24b-2 of the Securities Exchange Act of 1934, as amended.

5

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00158-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00158-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00158-of-00352.parquet"}]]